Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BCTX
stocks logo

BCTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2026Q2
FY2026Q3
--
--
-3.280
-90.06%
--
--
-4.840
-79.23%
--
--
-2.740
-83.29%
Estimates Revision
The market is revising No Change the revenue expectations for BriaCell Therapeutics Corp. (BCTX) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 55.53%.
Revenue Estimates for FY2026
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2026
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+55.53%
In Past 3 Month
Wall Street analysts forecast BCTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCTX is 39.90 USD with a low forecast of 39.90 USD and a high forecast of 39.90 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast BCTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCTX is 39.90 USD with a low forecast of 39.90 USD and a high forecast of 39.90 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 12.240
sliders
Low
39.90
Averages
39.90
High
39.90
Current: 12.240
sliders
Low
39.90
Averages
39.90
High
39.90
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$32
2025-04-22
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$32
2025-04-22
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Maintains
$15 → $32
2025-02-03
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$15 → $32
2025-02-03
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$15
2024-12-12
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$15
2024-12-12
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Briacell Therapeutics Corp (BCTX.O) is -1.10, compared to its 5-year average forward P/E of -3.28. For a more detailed relative valuation and DCF analysis to assess Briacell Therapeutics Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.28
Current PE
-1.10
Overvalued PE
-0.44
Undervalued PE
-6.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.61
Current PS
0.00
Overvalued PS
2.82
Undervalued PS
-1.60
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

BCTX News & Events

Events Timeline

(ET)
2025-12-02
07:40:00
BriaCell Presents Positive Phase 2 and 3 Data at 2025 San Antonio Breast Cancer Symposium
select
2025-12-01 (ET)
2025-12-01
07:30:00
Bicara Publishes Early Data on 750mg Ficerafusp Alfa for Head and Neck Cancer
select
2025-11-20 (ET)
2025-11-20
07:35:51
BriaCell and Receptor.AI Partner to Develop AI-Driven Small Molecule Cancer Treatments
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
11-25Newsfilter
BriaCell Presents Positive Clinical Data Across Three Studies at SABCS 2025
  • Clinical Data Highlights: BriaCell's presentation of positive Phase 2 data at the 2025 San Antonio Breast Cancer Symposium, along with biomarker findings from the Phase 3 study, reinforces confidence in its pivotal Phase 3 study for metastatic breast cancer, potentially driving future treatment developments.
  • Fast Track Designation: The Bria-IMT regimen has received Fast Track Designation from the FDA, which not only accelerates the clinical trial process but may also enhance investor confidence in the company's future market potential.
  • Extensive Presentation Opportunities: The company will showcase three posters at the symposium, covering biomarker and survival data, which is expected to attract significant attention from both industry insiders and outsiders, thereby enhancing brand visibility and fostering potential collaboration opportunities.
  • Insights into Mechanism of Action: The Chief Scientific Officer noted that the biomarker data provides crucial insights into the mechanism of action of the novel immunotherapy, which not only aids in the development of precisely targeted treatment options but may also improve clinical outcomes for patients, further solidifying the company's leadership in cancer immunotherapy.
[object Object]
Preview
9.0
11-18Newsfilter
BriaCell Chosen to Showcase Phase 2 and 3 Clinical Findings at SABCS® 2025

  • BriaCell's Presentations at SABCS: BriaCell Therapeutics will present three clinical and one preclinical posters at the 2025 San Antonio Breast Cancer Symposium, showcasing key biomarker data and survival results from their studies on Bria-IMT™ and other therapies for metastatic breast cancer.

  • Significant Data Sharing: The presentations include late-breaking clinical posters that aim to provide substantial data to leading breast cancer experts, with the goal of improving clinical outcomes for cancer patients.

  • Poster Presentation Details: Key presentations include topics on the impact of prior therapy and biomarkers in the Bria-ABC Phase 3 Trial, survival results from the Phase II Bria-IMT vaccine, and cytokine signatures as biomarkers of clinical benefit in breast cancer vaccination.

  • Company Overview: BriaCell is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance cancer care, with more information available on their website.

[object Object]
Preview
9.0
11-07Newsfilter
BriaCell Showcases Strong Anti-Cancer Effects of Bria-OTS+™ at SITC 2025

  • Bria-OTS+ Platform Overview: BriaCell Therapeutics has showcased its next-generation Bria-OTS+ platform, which demonstrates rapid and durable anti-cancer activity by engaging both innate and adaptive immune responses in preclinical models.

  • Preclinical Findings: The platform's lead candidates, Bria-BRES+ for breast cancer and Bria-PROS+ for prostate cancer, have shown strong immune activation and sustained anti-cancer responses, indicating potential for prolonged clinical benefits.

  • Broad Applicability: The positive results from Bria-BRES+ and Bria-PROS+ suggest the Bria-OTS+ platform could be expanded to treat other solid tumors, highlighting its ability to generate potent immune responses across various cancer types.

  • Future Clinical Trials: BriaCell plans to confirm these preclinical findings in upcoming Phase 1/2a clinical studies, with Bria-PROS+ supported by a $2 million National Cancer Institute award.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Briacell Therapeutics Corp (BCTX) stock price today?

The current price of BCTX is 12.24 USD — it has decreased -3.16 % in the last trading day.

arrow icon

What is Briacell Therapeutics Corp (BCTX)'s business?

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.

arrow icon

What is the price predicton of BCTX Stock?

Wall Street analysts forecast BCTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCTX is 39.90 USD with a low forecast of 39.90 USD and a high forecast of 39.90 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Briacell Therapeutics Corp (BCTX)'s revenue for the last quarter?

Briacell Therapeutics Corp revenue for the last quarter amounts to -8.55M USD, increased 48.31 % YoY.

arrow icon

What is Briacell Therapeutics Corp (BCTX)'s earnings per share (EPS) for the last quarter?

Briacell Therapeutics Corp. EPS for the last quarter amounts to -8132445.00 USD, increased 81.02 % YoY.

arrow icon

What changes have occurred in the market's expectations for Briacell Therapeutics Corp (BCTX)'s fundamentals?

The market is revising No Change the revenue expectations for BriaCell Therapeutics Corp. (BCTX) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 55.53%.
arrow icon

How many employees does Briacell Therapeutics Corp (BCTX). have?

Briacell Therapeutics Corp (BCTX) has 22 emplpoyees as of December 05 2025.

arrow icon

What is Briacell Therapeutics Corp (BCTX) market cap?

Today BCTX has the market capitalization of 23.06M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free